GH Research PLC (GHRS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GH Research PLC (GHRS) has a cash flow conversion efficiency ratio of -0.042x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.02 Million) by net assets ($359.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GH Research PLC (GHRS) market capitalisation for the company's overall valuation and market capitalisation.
GH Research PLC - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how GH Research PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
GH Research PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GH Research PLC ranked by their cash flow conversion efficiency. Explore how high is GH Research PLC's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Ellington Electronics Technology Co Ltd
SHG:603328
|
0.053x |
|
Sichuan Teway Food Group Co Ltd
SHG:603317
|
0.081x |
|
China Enterprise Co Ltd
SHG:600675
|
-0.088x |
|
Gudang Garam Tbk
JK:GGRM
|
0.061x |
|
Ruentex Industries Ltd
TW:2915
|
0.003x |
|
Wenzhou Yihua Connector Co Ltd
SHE:002897
|
-0.029x |
|
Spectrum Brands Holdings Inc
NYSE:SPB
|
0.044x |
|
Alsea S.A.B. de C.V
MX:ALSEA
|
0.054x |
Annual Cash Flow Conversion Efficiency for GH Research PLC (2019–2025)
The table below shows the annual cash flow conversion efficiency of GH Research PLC from 2019 to 2025. View GH Research PLC (GHRS) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $279.70 Million | $-43.55 Million | -0.156x | +34.10% |
| 2024-12-31 | $178.95 Million | $-42.28 Million | -0.236x | -55.21% |
| 2023-12-31 | $218.97 Million | $-33.34 Million | -0.152x | -45.17% |
| 2022-12-31 | $249.82 Million | $-26.20 Million | -0.105x | -90.20% |
| 2021-12-31 | $277.18 Million | $-15.28 Million | -0.055x | +5.33% |
| 2020-12-31 | $5.67 Million | $-330.00K | -0.058x | +91.94% |
| 2019-12-31 | $400.00K | $-289.00K | -0.723x | -- |
About GH Research PLC
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II… Read more